title: Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
abstract: BACKGROUND
  Noninvasive intraductal papillary mucinous neoplasms (IPMNs) have a favorable prognosis; however, the prognosis of invasive intraductal papillary mucinous carcinoma (invasive IPMC) is poor. Identification of predictive factors for differentiating IPMC from benign IPMNs would assist in providing appropriate treatment.
  
  
  METHODS
  Retrospective study (1999-2006).
  
  
  METHODS
  Wakayama Medical University Hospital, Wakayama, Japan.
  
  
  METHODS
  Fifty-four patients with IPMN who underwent surgery; histologic examination showed benign adenomas in 29, carcinoma in situ in 14, and invasive carcinoma in 11 patients.
  
  
  METHODS
  Clinical data, preoperative imaging findings, cytologic findings, tumor markers in serum and pancreatic juice, and overall survival.
  
  
  RESULTS
  Age of 70 years or older, presence of mural nodules, mural nodule size of 5 mm or larger, and carcinoembryonic antigen (CEA) level in pancreatic juice of 110 ng/mL or higher (as obtained by preoperative endoscopic retrograde pancreatography) were predictive of a malignant IPMN by univariate analysis, and a CEA level of 110 ng/mL or higher in pancreatic juice was identified as the only independent predictive factor for the malignant entity. The presence of jaundice or body weight loss, main pancreatic duct type, presence of mural nodules, mural nodule size of 5 mm or larger, and CEA level in the pancreatic juice of 110 ng/mL or higher were all predictive of invasive IPMCs by univariate analysis.
  
  
  CONCLUSIONS
  Measurement of the CEA level in pancreatic juice should be considered in the diagnosis of IPMC.
authors.affiliation: Second Department of Surgery, Wakayama Medical University, School of Medicine, Kimiidera, Wakayama, Japan.
authors.forename: Seiko
authors.initials: S
authors.lastname: Hirono
authors.forename: Masaji
authors.initials: M
authors.lastname: Tani
authors.forename: Manabu
authors.initials: M
authors.lastname: Kawai
authors.forename: Shinomi
authors.initials: S
authors.lastname: Ina
authors.forename: Ryohei
authors.initials: R
authors.lastname: Nishioka
authors.forename: Motoki
authors.initials: M
authors.lastname: Miyazawa
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Fujita
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yamaue
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D021441:Carcinoma, Pancreatic Ductal / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002291:Carcinoma, Papillary / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D015996:Survival Rate